Reversed mutation rates ofKRASandEGFRgenes in adenocarcinoma of the lung in Taiwan and their implications

摘要: BACKGROUND. In western countries, the Kirsten ras oncogene homolog gene (KRAS) mutation rate is high in patients with nonsmall cell lung cancer (NSCLC), especially those adenocarcinoma (30%-50%), but epidermal growth factor receptor (EGFR) very low (3%-8%). In addition, KRAS mutations reportedly were associated EGFR tyrosine kinase inhibitor (EGFR-TKI) resistance. Taiwan, rates EGFR-TKI response NSCLC have been reported; however, data are limited and not correlated TKI response. METHODS. KRAS analysis was performed on 237 specimens, results clinicopathologic features. All 2 tumors also underwent analysis. RESULTS. KRAS identified only 9 of (3.80%). Five women who nonsmokers, 4 men ever-smokers. The 5.03% (8 159 patients) 1.56% squamous carcinoma (1 64 patients). Four G12V, 3 G12D, 1 L19F, duplication insertion dupT50_M72. contrast, detected 96 235 (40.8%) 90 157 adenocarcinomas (57.3%). None coexisted mutations. significantly any characteristics, including smoking status. Among 53 had received monotreatment, patient a progressive disease. CONCLUSIONS. The too to play significant role resistance or tumorigenesis among Taiwanese NSCLC, which complete reverse reported countries. Cancer 2008. © 2008 American Society.